Is A261780 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A261780 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A261780's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A261780's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A261780?
Key metric: As A261780 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for A261780. This is calculated by dividing A261780's market cap by their current
book value.
What is A261780's PB Ratio?
PB Ratio
3x
Book
₩32.69b
Market Cap
₩98.78b
A261780 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: A261780 is expensive based on its Price-To-Book Ratio (3x) compared to the KR Biotechs industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is A261780's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
A261780 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
3x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate A261780's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.